About Amal Therapeutics

Amal Therapeutics SA is a Swiss biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated on September 3rd, 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.

Amal Therapeutics SA announces the appointment of Dr Johanna Holldack as Chairman

Meet us

March 2014
Amal Therapeutics to present at the European Life Science CEO Forum

Amal Therapeutics to present at the Biomed UP

April 2014
Amal Therapeutics to present at the Swiss Biotech Day